Sclerotherapy for congenital vascular malformations with mixing foam of polidocanol and liquid of bleomycin.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Phlebology Pub Date : 2023-08-01 DOI:10.1177/02683555231184772

Wei-Hong Yang, Xian-Jun Xiang, Hai-Lei Li

{"title":"Sclerotherapy for congenital vascular malformations with mixing foam of polidocanol and liquid of bleomycin.","authors":"Wei-Hong Yang, Xian-Jun Xiang, Hai-Lei Li","doi":"10.1177/02683555231184772","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy of sclerotherapy for congenital vascular malformation (CVM) using a combination of polidocanol foam and bleomycin liquid.Methods: A retrospective review of a prospectively collected data on patients who had sclerotherapy for CVM from May 2015 to July 2022 was performed.Results: A total of 210 patients with a mean age of 24.8 ± 2.0 years were included. Venous malformation (VM) was the most common type of CVM, accounting for 81.9% (172/210) of all patients. At 6 months follow-up, the overall clinical effective rate was 93.3% (196/210), and 50% (105/210) of patients were clinically cured. The clinical effective rates in VM, lymphatic, and arteriovenous malformation group were 94.2%, 100%, and 100%.Conclusion: Sclerotherapy using a combination of polidocanol foam and bleomycin liquid is an effective and safe treatment for venous and lymphatic malformations. It is a promising treatment option with satisfactory clinical outcome in arteriovenous malformations.","PeriodicalId":20139,"journal":{"name":"Phlebology","volume":"38 7","pages":"451-457"},"PeriodicalIF":1.6000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02683555231184772","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy of sclerotherapy for congenital vascular malformation (CVM) using a combination of polidocanol foam and bleomycin liquid.

Methods: A retrospective review of a prospectively collected data on patients who had sclerotherapy for CVM from May 2015 to July 2022 was performed.

Results: A total of 210 patients with a mean age of 24.8 ± 2.0 years were included. Venous malformation (VM) was the most common type of CVM, accounting for 81.9% (172/210) of all patients. At 6 months follow-up, the overall clinical effective rate was 93.3% (196/210), and 50% (105/210) of patients were clinically cured. The clinical effective rates in VM, lymphatic, and arteriovenous malformation group were 94.2%, 100%, and 100%.

Conclusion: Sclerotherapy using a combination of polidocanol foam and bleomycin liquid is an effective and safe treatment for venous and lymphatic malformations. It is a promising treatment option with satisfactory clinical outcome in arteriovenous malformations.

查看原文本刊更多论文

多元醇泡沫与博来霉素液体混合硬化治疗先天性血管畸形。

目的:评价聚多醇泡沫联合博来霉素液体硬化治疗先天性血管畸形(CVM)的疗效。方法:回顾性分析2015年5月至2022年7月前瞻性收集的CVM硬化治疗患者的数据。结果:共纳入210例患者，平均年龄24.8±2.0岁。静脉畸形(VM)是最常见的CVM类型，占所有患者的81.9%(172/210)。随访6个月，总临床有效率为93.3%(196/210)，50%(105/210)患者临床治愈率。VM畸形组、淋巴畸形组和动静脉畸形组的临床有效率分别为94.2%、100%和100%。结论:聚多卡因醇泡沫联合博来霉素液联合硬化治疗静脉和淋巴畸形是一种安全有效的治疗方法。它是治疗动静脉畸形的一种有希望的治疗方法，临床效果满意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555